In breast cancer, non-small cell lung cancer, gastric cancer, and prostate cancer, aberrant expression levels of HSPB1 have been associated with aggressive tumor behavior, chemotherapy resistance, and poor prognosis. The gene discussed is HSPB1; the disease is neoplasm.